Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$4.47M | -$3.86M | -$4.69M | -$6.63M | -$6.29M | -$7.85M | -$18.3M | -$34.7M | -$30.2M | -$58.2M |
| Net income | -$3.18M | -$3.09M | -$19.2M | $1.05M | -$6.56M | -$8.52M | -$19.5M | -$37.6M | -$26.6M | -$55.9M |
| EPS (diluted) | -$0.17 | -$0.11 | -$0.16 | -$0.05 | -$0.03 | -$0.02 | -$8.77 | -$5.37 | -$0.73 | -$1.41 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.55M | -$3.33M | -$3.94M | -$6.03M | -$6.05M | -$6.47M | -$12.7M | -$14.0M | -$25.2M | -$43.1M |
| Capital expenditures | $11.1K | $19.7K | $4.38K | — | $7.23K | $90.9K | $28.1K | $12.6K | $1.60M | $6.31K |
| Free cash flow | -$3.56M | -$3.35M | -$3.95M | — | -$6.06M | -$6.57M | -$12.8M | -$14.0M | -$26.8M | -$43.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $64.8K | $260K | $1.85M | $1.83M | $2.47M | $8.99M | $1.25M | $1.26M | $68.4M | $5.88M |
| Total assets | $323K | $557K | $1.96M | $2.00M | $2.67M | $9.86M | $9.11M | $11.9M | $72.8M | $28.3M |
| Total liabilities | $1.77M | $1.36M | $17.5M | $1.45M | $2.22M | $3.99M | $12.1M | $14.1M | $4.61M | $8.29M |
| Shareholders' equity | -$2.91M | -$3.57M | -$15.6M | $548K | $451K | $5.86M | -$3.01M | -$2.13M | $68.2M | $20.0M |
| Retained earnings | -$10.9M | -$14.0M | -$33.2M | -$32.2M | -$38.7M | -$47.3M | -$66.7M | -$104M | -$131M | -$187M |
| Shares (wtd avg diluted) | 18.9M | 27.9M | 121M | 170M | 231M | 407M | 2.22M | 7.01M | 36.5M | 39.7M |
Every figure is extracted from Skye Bioscience, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.